# tislelizUMaB in canceR Patients With molEcuLar residuaL Disease

> **NCT06332274** · PHASE3 · RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 717 (estimated)

## Conditions studied

- Cancer
- Lung Cancer
- Colo-rectal Cancer
- Pancreas Cancer
- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Tislelizumab
- **OTHER:** Blood sampling
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06332274
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-16
- **Primary completion:** 2029-04
- **Final completion:** 2030-04
- **Target enrollment:** 717 (ESTIMATED)
- **Last updated:** 2025-05-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06332274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06332274, "tislelizUMaB in canceR Patients With molEcuLar residuaL Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06332274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*